Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
AbbVie as a shareholder of Galapagos

About AbbVie as a shareholder of Galapagos, Jan De Kerpel says in De Tijd: “It gives a dual message to investors considering to subscribe to the c…

POPULAR TAGS

Only one stop more for Galapagos to market filgotinib

Written by DS on in the category news with the tags , .


Galapagos initiates the third and final test phase for filgotinib, a candidate drug to treat rheumatoid arthritis, a potential flagship product. They do this in collaboration with US partner Gilead.

The study consists of three different tests in which the effectiveness of filgotinib is tested both in patients having an early stage of rheumatoid arthritis as well as in patients who previously received other treatments.

Read all the Galapagos news here.

The start of these tests was expected: Last May, Galapagos received permission to perform these tests from the US and European authorities.

Gilead strongly believes in the potential of this drug as they paid several hundred million euros to acquire the license on this drug and they also financed most of the R&D. In combination with Galapagos's successful IPO on Nasdaq, Galapagos can now dispose of a budget of 1 billion euros.

Read more about: , .

RELATED ARTICLES
AbbVie as a shareholder of Galapagos

About AbbVie as a shareholder of Galapagos, Jan De Kerpel says in De Tijd: “It gives a dual message to investors considering to subscribe to the c…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK KU Leuven UGent V-Bio Ventures Janssen Biowin Flanders.bio Turnstone XpandInnovation Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.